Comparison of With and Without Sequential Single Drug Therapy of S-1 After Adjuvant Chemotherapy With Docetaxel Plus S-1 in Stage III Gastric Cancer
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Recurrence free survival
研究概览
简要总结
The goal of this single arm clinical trial is to learn about sequential S-1 adjuvant therapy in patient wich locally advanced gastric cancer. The main question it aims to answer is:
• The efficacy and safety of S-1 adjuvant therapy, following D2 radical surgery and DS(Docetaxel + S-1) adjuvant chemotherapy.
All patients with locally advanced gastric cancer will received D2 radical surgery, 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy up to 1 year postoperation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(1) Histologically or cytologically confirmed adenocarcinoma of the stomach or adenocarcinoma of the gastroesophageal junction;
- •(2) Radical surgery (D2 lymph node dissection) for gastric cancer in our center, with postoperative pathological stage of stage III;
- •(3) No significant tumor recurrence or metastasis as assessed by imaging;
- •(4) Age 18 years - 75 years;
- •(5) ECOG score of 0 or 1;
- •(6) Laboratory tests tolerant to chemotherapy;
- •(7) Hematological examination: no obvious signs of hematologic diseases, ANC ≥ 1.5 × 10^9/L, platelet count ≥ 80 × 10^9/L, Hb ≥ 90 g/L, WBC ≥ 3.0 × 10^9/L before enrollment, and no bleeding tendency; (8) Biochemical examination: total bilirubin < 1.5 times the upper limit of normal value, AST, ALT < 2.5 times the upper limit of normal value, creatinine < 1.5 times the upper limit of normal value.
排除标准
- •(1) Other pathological types of tumors;
- •(2) Pregnant or nursing women;
- •(3) Those with a history of other malignant neoplastic disease in the last 5 years;
- •(4) Those with a history of uncontrolled epilepsy, central nervous system disease, or psychiatric disorder, where the investigator determines whether the clinical severity prevents signing an informed consent form or affects the patient's compliance with oral medications;
- •(5) Clinically severe (i.e., active) heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or arrhythmias requiring pharmacologic intervention, or a history of myocardial infarction within the last 12 months;
- •(6) Severe diabetes-related complications, such as diabetic nephropathy, diabetic ketosis, etc;
- •(7) Those with digestive tract obstruction or physiological abnormalities, or suffering from malabsorption syndrome, which may affect S-1 absorption;
- •(8) Those who have had gastrointestinal bleeding in the last two weeks, or are at high risk of bleeding as judged by the investigator;
- •(9) Known to have peripheral nerve disease ≥ NCI-CTC AE grade
- •but with deep tendon reflexes (DTR) only;
- •(10) Those requiring immunosuppressive therapy for organ transplantation;
- •(11) who have received other chemotherapy regimens
- •(12) Those with uncontrolled severe infections, or other serious concomitant diseases;
- •(13) Allergic to S-1 or any of the study drug components.
研究组 & 干预措施
DS-S group
All patients pathologically confirmed pTNM stage III, will receive 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy till 1 year postoperation.
干预措施: Docetaxel (Drug)
DS-S group
All patients pathologically confirmed pTNM stage III, will receive 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy till 1 year postoperation.
干预措施: Tegafur-Gimeracil-Oteracil (Drug)
结局指标
主要结局
Recurrence free survival
时间窗: 3 years
Recurrence free survival
次要结局
- Overall survival(up to 5 years)
研究者
Jian Chen
head of Gastrointestinal department of second affiliated hospital of Zhejiang University
Zhejiang University